Jpmorgan Chase & CO Cyma Bay Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$12.63 - $24.47 $2.56 Million - $4.96 Million	-202,830 Reduced 55.92%	159,857 $3.78 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $660,005 - $1.07 Million	-60,774 Reduced 14.35%	362,687 $5.41 Million
Q2 2023 Aug 11, 2023	SELL	$7.47 - $10.95 $888,526 - $1.3 Million	-118,946 Reduced 21.93%	423,461 $4.64 Million
Q1 2023 May 11, 2023	BUY	$5.88 - $9.59 $3.17 Million - $5.17 Million	539,415 Added 18028.58%	542,407 $4.73 Million
Q4 2022 Feb 13, 2023	SELL	$3.22 - $6.27 $10,725 - $20,885	-3,331 Reduced 52.68%	2,992 $19,000
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $8,254 - $12,665	2,980 Added 89.14%	6,323 $22,000
Q2 2022 Aug 11, 2022	SELL	$1.72 - $3.39 $2.24 Million - $4.41 Million	-1,300,368 Reduced 99.74%	3,343 $10,000
Q1 2022 May 11, 2022	SELL	$2.77 - $3.64 $218,372 - $286,959	-78,835 Reduced 5.7%	1,303,711 $4.06 Million
Q4 2021 Feb 10, 2022	BUY	$3.23 - $4.6 $165,605 - $235,846	51,271 Added 3.85%	1,382,546 $4.67 Million
Q3 2021 Nov 12, 2021	BUY	$3.47 - $4.42 $4.62 Million - $5.88 Million	1,331,275 New	1,331,275 $4.86 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.